Literature DB >> 25698111

Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.

T R Lawson1, I E Brown1, D L Westerkam1, D W Blackhurst2, S Sternberg2, R Leacock2, T I Nathaniel1.   

Abstract

PURPOSE: Several clinical trials have highlighted general favorable outcomes of intravenous tissue type plasminogen activator (rt-PA) in acute ischemic stroke using different measures including, National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). Findings from most of these measures indicate that the benefits of rt-PA are time dependent, thus, supporting intensive efforts to fast-track hospital thrombolytic treatment in patients with stroke. Despite the widespread benefits of rt-PA, the effectiveness of this therapy on specific functions such as ambulatory performance of the recovering stroke patient is not fully investigated. We aim to investigate this issue in the current study.
METHODS: We analyzed data from a retrospective cohort of acute ischemic stroke patients admitted to Greenville Health System (GHS) between 2010-2013. We identified patients who received rt-PA within a 4.5 hour time frame following the onset of acute ischemic stroke symptoms. Our analysis compared ambulatory variables and hospital-level characteristics in proportions of patients receiving rt-PA with those not receiving rt-PA. This analysis determined whether early treatment with rt-PA is associated with favorable changes in ambulatory status from admission to discharge following acute ischemic stroke.
RESULTS: Among 663 patients with ischemic stroke who were eligible to receive rt-PA, 241 patients received rt-PA and 422 patients did not due to several risk factors. We found a statistically significant difference (P < 0.001) for changes in ambulation status from hospital admission to discharge between patients receiving rt-PA and patients who did not receive rt-PA. Among patients who received rt-PA, 27.8% improved in their ambulation status, 41.9% saw no change in their ambulation status, 0.4% worsened in their ambulation status, and 29.9% were unable to be determined. Of the patients who did not receive rt-PA, 20.1% improved in their ambulation status, 61.8% saw no change in their ambulation status, 1.4% worsened in their ambulation status, and 16.6% were unable to be determined.
CONCLUSION: Our current study indicates that early treatment with rt-PA may be associated with favorable changes in ambulatory status from admission to discharge following acute ischemic stroke.

Entities:  

Keywords:  Ambulation; acute ischemic stroke; tissue plasminogen activator (rt-PA)

Mesh:

Substances:

Year:  2015        PMID: 25698111     DOI: 10.3233/RNN-140480

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  14 in total

1.  Gender and thrombolysis therapy in acute ischemic stroke patients with incidence of obesity.

Authors:  Brice Blum; Alexandria Penwell; Leah Wormack; Brittany Walker; Shyyon Lari; Thomas I Nathaniel
Journal:  Neurol Sci       Date:  2019-05-02       Impact factor: 3.307

2.  Stroke Severity among Men and Women Acute Ischemic Stroke Patients in the Telestroke Network.

Authors:  Nicolas Poupore; Camron Edrissi; Mareshah Sowah; Madison Stanley; Jonah Joffe; Donovan Lewis; Teanda Cunningham; Carolyn Breauna Sanders; Krista Knisely; Chase Rathfoot; Thomas I Nathaniel
Journal:  Cerebrovasc Dis Extra       Date:  2022-06-08

3.  Gender differences in comorbidities and risk factors in ischemic stroke patients with a history of atrial fibrillation.

Authors:  Chase Rathfoot; Camron Edrissi; Carolyn Breauna Sanders; Krista Knisely; Nicolas Poupore; Thomas Nathaniel
Journal:  BMC Neurol       Date:  2021-05-25       Impact factor: 2.474

Review 4.  Brain Functional Reserve in the Context of Neuroplasticity after Stroke.

Authors:  Jan Dąbrowski; Anna Czajka; Justyna Zielińska-Turek; Janusz Jaroszyński; Marzena Furtak-Niczyporuk; Aneta Mela; Łukasz A Poniatowski; Bartłomiej Drop; Małgorzata Dorobek; Maria Barcikowska-Kotowicz; Andrzej Ziemba
Journal:  Neural Plast       Date:  2019-02-27       Impact factor: 3.599

5.  The telestroke and thrombolysis therapy in diabetic stroke patients.

Authors:  Thomas I Nathaniel; Chibueze Ubah; Leah Wormack; Jordan Gainey
Journal:  Diabetol Metab Syndr       Date:  2019-05-09       Impact factor: 3.320

6.  In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?

Authors:  Oluyemi R Rotimi; Iretioluwa F Ajani; Alexandria Penwell; Shyyon Lari; Brittany Walker; Thomas I Nathaniel
Journal:  Womens Health (Lond)       Date:  2020 Jan-Dec

7.  Intraventricular Medium B Treatment Benefits an Ischemic Stroke Rodent Model via Enhancement of Neurogenesis and Anti-apoptosis.

Authors:  Yun-An Chen; Yi-Chieh Tsai; Yi-Dao Chen; Der-Zen Liu; Tai-Horng Young; Li-Kai Tsai
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

8.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients.

Authors:  Tyler Fleming; Brice Blum; Benjamin Averkamp; James Sullivan; Thomas Nathaniel
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-23       Impact factor: 3.738

9.  Obstructive sleep apnea and stroke severity: Impact of clinical risk factors.

Authors:  Carolyn Breauna Sanders; Krista Knisely; Camron Edrissi; Chase Rathfoot; Nicolas Poupore; Leah Wormack; Thomas Nathaniel
Journal:  Brain Circ       Date:  2021-05-29

10.  Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Katherine Brown; Ashley Snell; Thomas I Nathaniel
Journal:  Lipids Health Dis       Date:  2020-05-06       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.